- videocam On-Demand
- signal_cellular_alt Intermediate
- card_travel Patent
- schedule 90 minutes
Drafting and Prosecuting Patent Applications to Withstand PTAB Scrutiny
Building Reasonable Claim Construction to Avoid Unpatentability and Using Declarations to Survive Post-Grant Proceedings
Welcome! Strafford is now BARBRI! The expert courses you know from the trusted global leader in legal education.
Description
IPRs remain weighted in favor of patent challengers, and the ability to amend, not just cancel, claims in post-grant proceedings has been rare. Institution rates, though declining from the first years of AIA post-grant proceedings, remain elevated, as do cancellation rates of instituted claims (still almost 2/3 of all Final Written Decisions find all challenged claims unpatentable, according to USPTO stats). Practitioners must act during drafting and prosecution to strengthen their potentially critical patent applications against PTAB scrutiny.
The initial objective for a patent owner is to have the petition denied. A well-drafted specification and file history, possibly including declarations presented therein, but making sure not to raise inequitable conduct/patent misuse issues, provide the basis for the patent owner's preliminary response and a means to avoid the institution of an IPR or PGR entirely or possibly even to achieve a settlement. Also, the patent owner should think about means plus function claims in pharmaceutical/chemical specifications, taking into account lessons learned from the Xencor and Chamberlain cases.
Listen as our authoritative panel offers concrete suggestions for drafting and prosecuting U.S. patent applications to seek the broadest reasonable claim interpretation while avoiding unpatentability before the PTAB. The panel will offer best practices to solidify novelty, non-obviousness, enablement, and written description positions.
Presented By

Ms. Burgy focuses on opinion work, client counseling, patent prosecution and management, and litigation in the chemical, pharmaceutical, and biotechnology arts. She counsels her clients on a diverse range of patent issues. She assists clients on single-patent issues as well as complex matters involving multiple patents and applications requiring ongoing advice on patent portfolio strategy and development, with an eye towards litigation. She has assisted clients in the early stages of development through due diligence and patent portfolio analysis.

Mr. Gutowski focuses on client counseling, patent procurement, and patent enforcement. He advises clients on patent matters relating to infringement, validity, due diligence, and licensing. He also focuses his practice on strategic patent portfolio growth, management, and utilization. He has prepared and prosecuted patent applications to patent issuance and has significant experience in securing patent protection outside the U.S. He has developed vast experience in complex USPTO proceedings such as interferences, appeals, reissues, and reexaminations.

Mr. Irving has 47 years of experience in the field of IP law. His practice includes due diligence, patent prosecution, reissue and reexamination, patent interferences, and counseling, including prelitigation, Orange Book listings of patents covering FDA-approved drugs, and infringement and validity analysis in the chemical fields, as well as litigation. He has served as lead counsel in many patent interferences.
-
This 90-minute webinar is eligible in most states for 1.5 CLE credits.
-
Live Online
On Demand
Date + Time
- event
Monday, July 15, 2024
- schedule
1:00 p.m. ET./10:00 a.m. PT
Outline
- Claim drafting strategies across various fields of technology
- Specification drafting strategies
- Prosecution strategies
- Continuation applications
- Carefully prepared declarations
- Judicious use of patent profanity to limit reasonability of broadest claim construction, at least in certain embodiments
Benefits
The panel will review these and other key issues:
- How can practitioners draft and prosecute patent applications and claims to minimize the threat and/or efficacy of a third-party's post-grant challenges?
- How can patent owners obtain broad claims to keep competitors at bay while countering attempts to render those claims unpatentable under the broadest reasonable interpretation standard before the PTAB? Is the equation different for patent owners in regulated fields such as pharmaceuticals.
- How can practitioners introduce substantial grounds for patentability under Sections 102, 103, and 112 in the specification and prosecution history?
Unlimited access to premium CLE courses:
- Annual access
- Available live and on-demand
- Best for attorneys and legal professionals
Unlimited access to premium CPE courses.:
- Annual access
- Available live and on-demand
- Best for CPAs and tax professionals
Unlimited access to premium CLE, CPE, Professional Skills and Practice-Ready courses.:
- Annual access
- Available live and on-demand
- Best for legal, accounting, and tax professionals
Unlimited access to Professional Skills and Practice-Ready courses:
- Annual access
- Available on-demand
- Best for new attorneys
Related Courses

Discretionary Denials in IPRs: New Framework, Navigating the Evolving Landscape, Strategies for Survival
Thursday, November 20, 2025
1:00 p.m. ET./10:00 a.m. PT

Terminating Patent Licenses: Key Considerations and Best Practices
Available On-Demand

Building a Winning Evidentiary Record at the PTAB (and Surviving Appeal)
Available On-Demand

Evaluating and Acquiring Patent Portfolios: Key Considerations
Available On-Demand